Information Provided By: 
Fly News Breaks for February 17, 2017
ICLR
Feb 17, 2017 | 08:44 EDT
UBS analyst Jonathan Groberg raised his price target on ICON plc to $105 from $86 following Q4 results. The analyst believes the company is well positioned to deliver on its 2017 guidance as the pharmaceutical industry continues to outsource more work. He also notes the company continued to expand its margins faster than the industry and sees management having the ability to minimize any earnings headwinds. Groberg reiterated his Buy rating on ICON plc shares.
News For ICLR From the Last 2 Days
There are no results for your query ICLR
